



DOYLESTOWN HOSPITAL RESEARCH JOINS DUAL ANTIPLATELET THERAPY (DAPT) TRIALS

Doylestown Hospital Medical Research Department is about to embark on a three-pronged clinical study approach to investigate the duration of dual antiplatelet therapy (aspirin plus a thienopyridine, i.e. Plavix™) in patients receiving drug-eluting stent (DES) implantations. We are currently enrolling in the Xience-V DAPT Trial, and are awaiting IRB approval in the Harvard Clinical Research Institute Trial (HCRI DAPT), and the Cypress DAPT Trial. Doylestown Hospital is one of 219 centers in North America and Europe which will be participating in these FDA sanctioned studies slated to enroll a total 20,645 patients. (HCRI is an FDA sponsored trial while Xience V and Cypress are manufacturer-sponsored trials.)

Nearly 700,000 patients a year are implanted with drug-eluting stents (DES), a treatment that has proven considerably more effective than implantation with bare metal stents (BMS). However, the FDA is concerned that DES might lead to higher rates of stent thrombosis. Clinical experts concur that the risk of stent thrombosis can be reduced by administering dual antiplatelet therapy (DAPT) to patients for an extended duration. But clinical trials conducted on any of the five FDA-approved DESs have not validated the optimal duration of DAPT administration following stent implantation. Additionally, although extending the duration of DAPT administration may lower the risk of very late stent thrombosis, this strategy could also result in an increased risk for major bleeding complications.

There is currently a lack of data regarding the optimal duration of dual-antiplatelet therapy following coronary stenting. As a result, considerable uncertainty surrounds the question as to whether the duration of dual therapy in patients receiving DES should be 12 months (as per ACC/AHA guidelines) or longer in patients without contraindication. It is also unclear whether the presumed benefit of extended thienopyridine administration is specific to DES or whether non-acute coronary syndrome patients (e.g., those with stable angina) treated with bare metal stents (BMS) may also benefit from extended dual antiplatelet therapy. **The DAPT trials are designed, conducted and analyzed to provide data to answer these questions.**

Due to the large sample size necessary for this study to detect small, but clinically important differences in clinical outcomes between treatment groups (12 months vs. 30 months of dual antiplatelet therapy), the FDA is allowing additional data to be contributed to the final DAPT Study analysis from a limited number of patients who are enrolled in stent manufacturer-sponsored studies. The manufacturer-sponsored studies have been designed to reproduce the DAPT randomization of 12 versus 30 months of thienopyridine therapy. The manufacturer studies follow the same data collection, adjudication, and analytic processes as the HCRI DAPT Study. "We anticipate the DAPT Trial results will be instrumental in establishing definitive guidelines. As an industry leader, Abbott is proud to play a significant role in contributing patients to this important study" (Abbott Vascular—Xience V DAPT). The final study analysis performed by HCRI will include data from subjects enrolled by HCRI and from subjects enrolled in the manufacturer-sponsored studies. (Dept. of HHS).

A recent letter from the FDA dated August 18, 2009, states, "We are very interested in moving forward with rapid study initiation and enrollment. We are writing today to provide the background information about the DAPT study to facilitate expeditious review of the DAPT study protocol by IRBs at the individual study sites and by the Centers for Medicare & Medicaid Services (CMS). "FDA is hoping for rapid enrollment into the DAPT study to answer critical public health questions related to stent use and antiplatelet therapy. It is anticipated that the results of the DAPT Study will contribute significantly to the scientific literature regarding the optimal use of antiplatelet therapy and will guide care in patient treated with coronary stents."

We look forward to working with our physicians on these important trials.



ARANESP

Amgen Inc. Protocol #: 20070196

Evaluation of Monthly Darbepoetin alfa Dosing for the Treatment of Anemia in Chronic Kidney Disease Patients not receiving Dialysis: An Active-controlled, Double-Blind Study.

The purpose of the study, sponsored by Amgen, Inc. is to demonstrate that darbepoetin alfa is safe and effective when switched from twice a month to monthly dosing to treat anemia in subjects with CKD not receiving dialysis, thus providing greater convenience to subjects and caregivers.

The study will include approximately 406 subjects from 150 medical centers.

All subjects will receive darbepoetin alfa. Patients will be randomized to receiving the drug either every two weeks or once a month and placebo at every other treatment visit. The study is expected to last up to 56 weeks.

The Primary Investigator for this study is Melchior Vernace, MD.

"The needs of the patient come first. These needs are best served when patients receive personal care that is high quality, cost effective and evidence based."
Mayo Research Clinic

DUO FLAIR	A-flutter Ablation	Start-Up	Drs. Sangrigoli & Sloan	0
SAPPHIRE WW	Carotid Stenting	Enrolling	Jos. McGarvey, Jr., M.D.	31
ARANESP	Anemia in CKD	Start-Up	Melchior Vernace, M.D.	0
HCRI	Dual Antiplatelet Therapy	Start-Up	Steven Guidera, M.D.	0
TRACER	Thrombin Inhibitor ACS	Enrolling	Jos. McGarvey, Jr., M.D.	15
ATLAS	Factor 10A Inhibitor	Enrolling	Steven Guidera, M.D.	14
CORAL	Renal Stenting vs. Med. Management	Enrolling	Jos. McGarvey, Jr., M.D.	12
CAPTURE II	Carotid Stenting	Enrolling	Steven Guidera, M.D.	42
CYPRESS	Dual Antiplatelet Therapy	Start-Up	Steven Guidera, M.D.	0
XIENCE V-DAPT	Dual Antiplatelet Therapy	Start-Up	Steven Guidera, M.D.	0
TRA 2P TIMI 50	Thrombin Inhibitor	Enrolling	James Kmetzo, M.D.	20
SATURN	Atherosclerosis IVUS	Follow-Up	Jos. McGarvey, Jr., M.D.	2
MERCK Vaccine	Staph vaccine	Enrolling	Joseph Auteri, M.D.	2
EMPHASIS	Class II Heart Failure	Enrolling	Renee Sangrigoli, M.D.	4
TRITON REGISTRY	Prior ACS Triton Patients	Follow-Up	Steven Guidera, M.D.	8
HORIZONS	Acute MI	Follow-Up	Jos. McGarvey, Jr., M.D.	2
CYPHER ELITE	Drug Eluting Stent	Follow-Up	Steven Guidera, M.D.	11
XIENCE-V	Drug Eluting Stent	Follow-Up	Steven Guidera, M.D.	56
TRIDENT	Heart Failure-Adenosine Antagonist	Follow-Up	Drs. McGarvey,Jr./Vernace	2
LEAP	Phosphate Binder/Dialysis Patients	Follow-Up	Melchior Vernace, M.D.	2
LIBRA	Hyponatremia	Enrolling	Melchior Vernace, M.D.	0
			TOTAL ENROLLMENT	223